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Abstract
Background: To determine the most effective route of administration of corticosteroids in the treatment of ocular
surface disease, by characterizing the difference between oral prednisolone and topical dexamethasone administration
using an animal model.
Methods: Pharmacokinetic analyses determined the corticosteroid concentrations in the normal ocular tissues of
rabbits after oral or topical administration of corticosteroids using LC-MS/MS. In wound healing analyses, the area of
the epithelial defect created by keratectomy using a 6-mm trephine was calculated with an image analyzer using an
orally or topically steroid-administrated animal model. The average size of basal epithelial cells, the frequency of mitotic
basal epithelial cells, the number of squamous cells, and the number of hypertrophic stromal fibroblasts were
determined in the enucleated corneal tissues after wound closure.
Results: By slit lamp examination, no remarkable differences were observed between orally and topically administered
groups. Pharmacokinetic analyses showed that the distribution of dexamethasone after topical administration was
superior to that after oral administration in the cornea. In contrast, both concentrations of corticosteroid applied
topically and orally were similar with regards to AUCs (area under the concentration-time curve) in the conjunctiva.
Although the healing rate was slower in the topical group, all corneas were almost healed within 96 h in the wound
healing analysis. According to the histological analyses of epithelial cells, the average basal cell size was larger, the
frequency of mitotic basal cells was greater, and the number of squamous epithelial cell layers was lower in the
topically administered group although all of these differences were with no statistical significance. However, the
number of hypertrophic stromal fibroblasts in the topically administered group was significantly lower than that in the
orally administered group.
Conclusions: There are different distributions and effects between orally and topically administered corticosteroids on
the ocular surface. The data may provide the useful information in selecting the appropriate route of corticosteroid
application for the treatment of ocular surface disease.
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Background
The administration of corticosteroids is an effective treat-
ment for various kinds of ocular surface diseases, including
treatment of allergic keratoconjunctivitis, autoimmune
keratitis, recurrent corneal erosion due to dystrophy, acute
hydrops of keratoconus, and endothelial dysfunction, al-
though the use of corticosteroids in the treatment of infec-
tious keratitis is still a controversial issue [1–6]. In such a
condition of ocular surface, corticosteroids are adminis-
tered by an oral or topical route. It is well-known that the
bioavailability of oral corticosteroids is very high, with al-
most 100 % of the corticosteroid being absorbed. Although
various kinds of oral corticosteroids are used, prednisolone
is most often used in treatment of ocular surface, because
of its moderate glucocorticoid effects, mild effects of elec-
trolyte metabolism, and moderate half-life. On the other
hand, topically applied corticosteroid will be expected to
be high concentrations on ocular surface at the time of ap-
plication and rapidly decrease by excretion of tears through
the lacrimal duct. In our clinical experience, there were
many patients who needed anti-inflammatory drugs in the
treatment. However, there is no definitive evidence con-
cerning which route of drug application is most suitable
for each corneal disease. Therefore, it is important to ob-
tain basic data about the differences between oral versus
topical administration of corticosteroid.
The primary concern of topical steroid use for ocular
surface diseases is delayed corneal epithelial wound heal-
ing [7, 8]. Occasionally, oral rather than topical cortico-
steroids are preferred in the case of corneal erosions to
prevent delayed wound healing and secondary infection.
However, the choice of oral or topical administration of
steroids is often empirically based and not evidence
based. In this report, we examined the differences in
pharmacokinetics and wound healing of corticosteroids
administered via either an oral or topical route using an
animal model.
Methods
Thirty-two male Japanese white rabbits (Kbl:JW; Kitayama
Labes Co., Ltd., Nagano, Japan) weighing 2.6–3.2 kg were
used in this study. All animals were treated and cared for
in compliance with the Guiding Principles in the Care and
Use of Animals. This study was approved and monitored
by the Institutional Animal Care and Use Committee of
Santen Pharmaceutical Co., Ltd., and all of the procedures
were performed according to the Association for Research
and Vision in Ophthalmology (ARVO) Statement for the
Use of Animals in Ophthalmic and Vision Research.
Pharmacokinetic analyses
Group 1 included 10 rabbits that orally received prednis-
olone (Sigma-Aldrich Japan, Tokyo, Japan), once a day for
3 days (0.25 mg/kg/day). Group 2 included 10 rabbits that
received topical dexamethasone eye drops (0.1 % Sante-
son® ophthalmic solution; Santen Pharmaceutical Co.,
Ltd., Osaka, Japan) twice a day for 2 days, and once a day
on the third day due to the euthanizing time schedule. On
the third day, two rabbits from each group were eutha-
nized at 0.5, 1, 2, 4, and 6 h after the final corticosteroid
administration with an overdose of sodium pentobarbital
(Somnopentyl®, Kyoritsu Seiyaku Co., Tokyo, Japan). After
both eyes were enucleated, the cornea and conjunctiva
were collected and stored at −80 °C until analysis (four
eyes from two animals at each time point). The cor-
ticosteroid concentrations in the cornea and conjunc-
tiva were determined using liquid chromatography/
mass spectrometry (LC-MS/MS; Prominence/API4000;
Shimadzu/Applied Biosystems, Kyoto, Japan).
Wound healing analyses
Under general anesthesia and topical anesthesia, a round
epithelial wound was created in the central cornea of the
left eye of each rabbit by performing a 0.15-mm deep
keratectomy with a 6-mm trephine. Based upon the ap-
proved experimental protocol, the right eye was used as
the untreated control. The rabbits were randomly assigned
to three experimental groups, with each group containing
four rabbits.
Group 1 received prednisolone orally once a day for
5 days (0.25 mg/kg/day), Group 2 received 0.1 % topical
dexamethasone eye drops twice a day for 5 days, and
Group 3 (the control group) received saline eye drops twice
a day for 5 days. All animals received antibiotic eye drops
(1.5 % Cravit® ophthalmic solution, Santen Pharmaceutical
Co., Ltd.) twice a day to prevent secondary infection.
All eyes were examined under a slit lamp biomicro-
scope (SL-15; Kowa Company, Ltd., Tokyo, Japan) at 0,
24, 48, 72, and 96 h after the wounding. The area of the
epithelial defect was stained with fluorescein (Sigma–Al-
drich) and photographed (Nikon Corporation, Tokyo,
Japan). The total area of the defect was calculated with
an image analyzer (WinRoof; Mitani Co., Tokyo, Japan).
On the fifth day, the conjunctival injection and the stro-
mal opacity were scored on a four point scale in a
double blind manner (−, not remarkable; ±, slight; +,
mild; ++, moderate; and +++, severe). One hour after
the final corticosteroid administration on the fifth day,
all rabbits were euthanized by exsanguination under
deep anesthesia induced by a Somnopentyl® intravenous
injection. Corneal specimens were obtained by enucle-
ation and were histologically examined.
Histological analyses
The excised tissues were immersed in F-G solution (9:1 of
10 % formaldehyde and 25 % glutaraldehyde) for 24 h and
subsequently fixed with 10 % neutral-buffered formalin.
Specimens were embedded in paraffin, cut into 4-μm
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thick sections, and mounted on slides. After deparaffiniza-
tion, samples were stained with hematoxylin and eosin
(H&E) and periodic acid-methenamine silver (PAM) to
identify the basal membrane. The wounded area was
observed under a scanning microscope (NanoZoomer;
Hamamatsu Photonics, Shizuoka, Japan).
The area of the basal epithelial cell layer was measured
with an image analyzer (HistoQuest; TissueGnostics,
Vienna, Austria), and the number of basal epithelial cells
was counted on PAM-stained slides. The average size of
basal cells was calculated as dividing the basal cell layer
areas by the number of basal cells. The frequency of mi-
totic basal epithelial cells was determined as dividing the
total number of cells with a proliferated nucleus by the
number of basal cells. The number of squamous cell
layers was counted on H&E-stained slides, and that of
hypertrophic stromal fibroblasts was counted and calcu-
lated as the number of cells per 1 mm2.
All values are expressed as the mean ± SEM. The data
were analyzed using Tukey’s multiple comparison tests. A
P-value of < 0.05 was considered statistically significant.
Results
Slit lamp examination
Table 1 shows the scores for the conjunctival injection
and stromal opacity 96 h after the wound was created.
Both scores were high in the saline group (Group 3). No
remarkable differences were observed between orally
and topically administered groups.
Pharmacokinetic analyses
The concentration-time curves of corticosteroids in ocu-
lar tissues are shown in Fig. 1. In the cornea, dexametha-
sone concentrations in the topically administered group
(Group 2) showed a high Cmax (133 ng/g) at 0.5 h after
administration, and the area under the concentration-
time curve (AUC0–6 h) was 204 ng · h/g. Prednisolone in
the oral administered group (Group 1) was maintained
at a low concentration throughout the observation
period; Cmax and AUC0–6 h were 6.8 ng/g and 26.5 ng ·
h/g, respectively. However, in the conjunctiva of the oral
administered group (Group 1), prednisolone concentra-
tions were constantly maintained at 20–30 ng/g for 2 h
after dosing. The dexamethasone concentration in the
topically administered group (Group 2) increased
(66.1 ng/g at 0.5 h) soon after the administration and
immediately decreased at 2 h. AUC0–6 h values in the
conjunctiva for the orally administered group (prednisol-
one) and topically administered group (dexamethasone)
were 81.3 and 113 ng · h/g, respectively.
Thus, in the cornea, the corticosteroid distribution
after topical administration was superior to that after
oral administration. However, in the conjunctiva, dexa-
methasone and prednisolone concentrations were simi-
lar, based upon the AUCs.
Wound healing
Representative photographs from each group are shown
in Fig. 2. The epithelial defect was slightly larger in the
topically administered group (Group 2) than in the orally
administered group throughout the observation periods.
However, corneal erosions were almost completely
healed within 96 h in all three groups. In Fig. 3, the
wound healing process is shown as a change in the area
of the epithelial defect. Four eyes still showed epithelial
defects of 2.4 mm diameter at 96 h in group 2. The







Animal No. 1 2 3 4 9 10 11 12 13 14 15 16
Conjunctival injection – – – – – – – + – ++ – ±
Stromal opacity ++ – ± + ± + – ++ ++ ++ + +
No. number
–: not remarkable, ±: slight, +: mild, ++: moderate, +++: severe
Fig. 1 Corticosteroid concentration in the cornea and conjunctiva using
oral and topical administration. Corticosteroid concentration in the
cornea (a) and in the conjunctiva (b) using oral administration (Group 1)
and topical administration (Group 2). Although corticosteroids
administered orally did not sufficiently reach the cornea, this route
maintained constant corticosteroid levels in the conjunctiva. The data are
expressed as the mean ± SD (4 eyes from 2 animals at each time point)
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healing rate was slightly slower in the topically adminis-
tered group (Group 2) than in the other two groups, but
this difference was not significant.
Histological analyses
There were some differences in basal epithelial cells be-
tween the topically and orally administered groups by
histological analysis (Fig. 4). The average basal cell size
was largest in the topically administered group (Group 2)
and smallest in the orally administered group (Group 1),
although these differences were not significant (15.9 ±
1.7 μm2 in Group 1, 18.4 ± 1.7 μm2 in Group 2, and 17.4
± 1.6 μm2 in Group 3). The frequency of mitotic basal
cells was highest in the topically administered group
(Group 2) and lowest in the orally administered group
(Group 1) (1.0 ± 0.4 % in Group 1, 3.5 ± 1.8 % in Group 2,
and 2.8 ± 1.1 % in Group 3). The number of squamous cell
layers was lowest in the topically administered group
(Group 2) with no statistical significance (3.0 ± 0.4 in
Group 1, 2.3 ± 0.3 in Group 2, and 2.8 ± 0.3 in Group 3).
The number of hypertrophic stromal fibroblasts was sig-
nificantly lower in the topically administered group
(Group 2) than in the other groups (116.8 ± 12.3 in Group
1, 69.5 ± 7.4 in Group 2, and 126.5 ± 18.2 in Group 3;
Fig. 5a and b).
Discussion
This is the first study that reports differences between
oral and topical administration of corticosteroids on the
ocular surface. Although there are many studies report-
ing differences between corticosteroid and nonsteroidal
anti-inflammatory drugs on the ocular surface, there
have been no studies reporting the differences based on
the application route of the corticosteroids. In pharma-
cokinetic analyses, corticosteroids reach the cornea bet-
ter when administered topically than orally, as was
expected. High concentrations of corticosteroid were
found just after topical application, and were soon
followed by a rapid decreased in a few hours. This de-
crease will be more rapid in humans than in animal
models because of the volume of tears. In contrast, only
small amounts of corticosteroids by oral route reached
the cornea. In conjunctiva, both of orally and topically
administered corticosteroids were well distributed. Al-
though the AUCs in conjunctiva were similar in both
routes, oral administration maintained corticosteroid
concentrations for a longer time period. Thus, cortico-
steroid through oral administration controls conjunctival







Fig. 2 Wound healing by group. A representative case of wound
healing by oral administration (Group 1), topical administration
(Group 2), and by the control group (Group 3). Although the erosion
present at 72 h appears to be greater in Group 2, this difference was
not significant
Fig. 3 Wound healing as shown by the slope of the corneal erosion
area. Although the wound healing was delayed in Group 2, erosion
almost completely healed at 96 h. The data are expressed as the
mean ± SEM of 4 eyes
Group 1 (oral) Group 2 (topical)
Group 3 (saline)
Fig. 4 The flattened epithelium consisted of two layers in Group 2.
Note the presence of three or more layers in Groups 1 and
3. Bar = 50 μm
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inflammation better than topical administration and top-
ical administration will be recommended to control the
corneal inflammation. In the case of a wounded and dis-
eased cornea, topical administration may provide a higher
concentration than in a normal cornea, because of the
lack of an intact epithelial barrier. Therefore, analyses of
the pharmacokinetics in injured tissues should be investi-
gated in future studies. In this experiment, we tried to re-
move various kinds of influences caused by the insults,
and used only normal corneas. On slit lamp examination,
we could not detect remarkable differences between cor-
ticosteroid and saline treatment regarding the grade of
corneal opacity. However, less scarring after steroid appli-
cation is often observed in clinical cases. This well-known
phenomenon might be related to the differences in num-
bers of hypertrophic stromal fibroblasts observed in our
studies. Thus, topical corticosteroid may be used if less
scar tissue and opacity are required on the optic axis, and
the corticosteroid should be applied orally if a reduction
of scleral and ciliary inflammation is required.
We have applied 0.1 % dexamethasone eye drops twice
a day as topical administration and 0.25 mg/kg prednis-
olone daily as an oral administration. These amounts of
corticosteroid and the kinds of corticosteroids are based
on our clinical doses.
The most controversial issue regarding topical cortico-
steroid use is delayed wound healing. Some previous stud-
ies reported a significant decrease in epithelial healing
after steroid treatment [7, 8], while other studies reported
the absence of such effects on corneal epithelial wound
healing in humans and animals [9, 10]. We found that
epithelial wound healing was delayed with topical cortico-
steroid administration, although this delay was not sig-
nificant. The large basal cell size, high mitotic rate, and
low squamous cell layers in group 2 indicated poor cell
differentiation when treated with topical corticosteroid.




Fig. 5 Stromal fibroblasts. The number of stromal fibroblasts was lower in Group 2 (topical steroid administration) as indicated by histological
analyses (a, bar = 100 μm) and statistical significance [b, mean ± S.E.M, n = 4; *P < 0.05 versus Group 3 (saline)]
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However, a high mitotic rate in group 2 and complete
healing of most corneas at 96 h even with topical corti-
costeroids (Group 2) suggest that topically administered
corticosteroids do not always result in persistent corneal
erosion. A longer time and larger scale examination will
be required to confirm the conclusions regarding wound
healing by corticosteroids. At present, our observations
suggest that topical corticosteroids should be switched to
an oral route when delayed epithelial healing is observed
in clinical cases.
In choosing the route of steroid application in clinical
practice, there may be other limitations such as intes-
tinal absorption and movement disorders affecting the
hands and the loss of visual acuity, which are essential
to apply the eye drops. Usage of topical corticosteroid
might also cause secondary infections on ocular surfaces.
Although corticosteroids compromise the ocular surface,
previous studies have shown that they do not affect the
minimum inhibitory concentration of antibiotics or the
proliferation of the organism [11–14].
In summary, we have shown different effects of cortico-
steroids on the ocular surface. These data may be useful
in choosing the application route of anti-inflammatory
treatments in ocular surface diseases. However, further
larger scale investigations using various concentrations of
different types of corticosteroids on injured or uninjured
corneas should be conducted in future studies.
Conclusions
This study showed the distributions and effects of orally
and topically administered corticosteroids on the ocular
surface. The data contributes to show the useful informa-
tion in choosing the method of corticosteroid application
for the treatment of ocular surface disease.
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